Monte Rosa Therapeutics, Inc. Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)
Monte Rosa Therapeutics, Inc. (GLUE) reported Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) of $2.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan › Defined Benefit Plan, Roll Forwards
us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2025 was $2.01M.
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2024 was -$907.00K.
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2023 was $0.00.
| Period end | Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|
| 2025-12-31 | $2.01M 10-K · filed 2026-03-17 |
| 2024-12-31 | -$907.00K 10-K · filed 2026-03-17 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |